International Stem Cell CORP

8-K · intlstemcell_8k.htm iXBRL

0001355790

 2026-06-11
 2026-06-11

 iso4217:USD

 xbrli:shares

 iso4217:USD

 xbrli:shares

  

  

 UNITED STATES

 SECURITIES AND EXCHANGE
COMMISSION

 WASHINGTON, D.C. 20549

  

 FORM 8-K

  

 CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

  

 Date of report (Date of earliest event reported):
 June 11, 2026

   

  

  

 INTERNATIONAL STEM CELL CORPORATION

 (Exact name of registrant as specified in its
charter)

  

  

  

 Delaware
 000-51891
 20-4494098

 (State or other jurisdiction

 of incorporation)

 (Commission

 File Number)

 (IRS Employer

 Identification Number)

  

 9745 Businesspark Ave , San Diego , California
 92131

 (Address of principal executive offices, including
zip code)

  

 (760) 940-6383

 (Registrant’s telephone number, including
area code)

  

 N/A

 (Former name or former address, if changed
since last report)

  

  

 Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

  

 ☐
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  
  

 ☐
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  
  

 ☐
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)

  
  

 ☐
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CAR 240.13e-4(c))

  

 Securities registered pursuant to Section 12(b) of the Act:

  

 Title of each class

 Trading Symbol(s)

 Name of each exchange on which registered

 None
 N/A
 N/A

  

 Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

  

 Emerging growth company   ☐

  

 If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

  

  

  

      

  

  

 ITEM 5.07 Submission of Matters to a Vote of Security
Holders

  

 International Stem Cell Corporation (the “Company”)
held its Annual Meeting of Stockholders on June 11, 2026. The stockholders considered one proposal, which is described in more detail
in the Company’s definitive proxy statement dated April 24, 2026.

  

 Proposal 1:
 Election of four directors to hold office until the 2027 Annual Meeting:

  

  
 A.
 Directors elected by holders of Series D Preferred Stock:

  

  
 FOR
  
 WITHHELD
  

 Andrey Semechkin
 2,457,143
  
 0
  

 Russell Kern
 2,457,143
  
 0
  

   

  
 B.
 Directors elected by holders of all shares of stock (including shares of preferred stock voting on an as-converted basis):

  

  
 FOR
  
 WITHHELD
  

 Donald A. Wright
 9,288,444
  
 30,590
  

 Paul V. Maier
 9,288,500
  
 30,534
  

  

 Broker Non-Votes: none

  

 All of the foregoing candidates were elected.

  

  

  

  

  

  

  

  

  

  

  

   2  

  

  

 SIGNATURES

  

  

 Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

  

  
 INTERNATIONAL STEM CELL CORPORATION

  
  
  

  
  
  

 Date: June 12, 2026
 By:
 /s/ Russell Kern

  
  
 Russell Kern

  
  

 Executive Vice President,

 Chief Scientific Officer and

 Principal Financial Officer

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

   3